dr. reddy's labs glp-1 receptor agonists weight management diabetes treatments Laboratories has received approval from Health Canada for its generic semaglutide injection, strengthening the Indian drugmaker's presence in the fast-growing global market for therapies. The company said on dr. reddy's labs glp-1 receptor
Description
Although rare, associations with nonarteritic anterior ischemic optic neuropathy, pancreatitis, medullary thyroid carcinoma, and acute kidney injury (AKI) have been reported, primarily through pharmacovigilance and case-based evidence
The GLP-1 Receptor Agonist market size is expected to reach $18.32 billion in 2030 at a CAGR of 5.4%, driven by rising prevalence of diabetes.
It is not approved yet, but the data is starting to demand attention
For users this could segway into an expansion of the private market and for payers this could provide an affordable entry point for public reimbursement
